COMUNICADO: Halaven® (eribulina) en combinación con capecitabina proporciona un beneficio clínico en mujeres con cáncer de mama meta

2. Smith JW. et al. Eribulin mesylate plus capecitabine for adjuvant treatment in post-menopausal ER+ early-stage breast cancer: a phase 2, multicenter, open-label study using 2 different dosage regimens. Abstract #P3-09-09

3. Schwartzberg LS. et al. Quality of life in patients receiving first-line eribulin mesylate for HER2- locally recurrent or MBC. Presented at SABCS 2014. Abstract P5-17-02

4. Schwartzberg LS. et al. Quality of life results from a phase 2, multicenter, single-arm study of eribulin mesylate plus trastuzumab as first-line therapy for locally recurrent or metastatic HER2+ breast cancer. Presented at SABCS 2014. Abstract #P5-17-03

5. Cortes J et al Efficacy of eribulin in patients with invasive lobular carcinoma of the breast: data from a pooled analysis. Presented at SABCS 2014. Abstract #P3-13-06

6. Cortes J et al. Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. The Lancet. 2011;377:914-923

7. Kaufman P et al. A Phase III, open-label, randomised, multicenter study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with anthracyclines and taxanes. Presented at 2012 CTRC-AACR San Antonio Breast Cancer Symposium

8. SPC Halaven (updated June 2014). Available at: http://www.medicines.org.uk/emc/medicine/24382/SPC/Halaven+0.44+mg+ml+solution+for+injection Accessed: December 2014

9. World Health Organisation. Atlas of Health in Europe. 2003. World Health Organization, Regional Office of Europe, Copenhagen, Denmark.

10. Cancer Research UK. Breast cancer incidence statistics. Available at: http://www.cancerresearchuk.org/cancer-info/cancerstats/types/breast/incidence/#world . Accessed: December 2014

11. Montazeri A et al. Quality of life in patients with breast cancer before and after diagnosis: an eighteen months follow up study. BMC Cancer. 2008. 3:330

Fecha de preparación: diciembre de 2014
Código de trabajo: Halaven-UK0371d

CONTACTO: Consultas de los medios de comunicación: Eisai Europe Ltd:Cressida Robson / Ben Speller, +44(0)7908-314-155 / +44(0)7947-231-513,Cressida_Robson@eisai.net / Ben_Speller@eisai.net. Tonic LifeCommunications: Ainsley Cooper / Claire Johnson, +44(0)207-798-1010 /+44(0)207-798-9929, ainsley.cooper@toniclc.com / claire.johnson@toniclc.com

WhatsAppFacebookTwitterLinkedinBeloudBluesky